Literature DB >> 17496428

Bispecific antibodies: molecules that enable novel therapeutic strategies.

Nicolas Fischer1, Olivier Léger.   

Abstract

Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials. Copyright (c) 2007 S. Karger AG, Basel.

Mesh:

Substances:

Year:  2007        PMID: 17496428     DOI: 10.1159/000101046

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  27 in total

1.  Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity.

Authors:  Jianying Dong; Arlene Sereno; William B Snyder; Brian R Miller; Susan Tamraz; Adam Doern; Michael Favis; Xiufeng Wu; Hon Tran; Emma Langley; Ingrid Joseph; Antonio Boccia; Rebecca Kelly; Kathleen Wortham; Qin Wang; Lisa Berquist; Flora Huang; Sharon X Gao; Ying Zhang; Alexey Lugovskoy; Shelly Martin; Heather Gouvis; Steven Berkowitz; Gisela Chiang; Mitchell Reff; Scott M Glaser; Kandasamy Hariharan; Stephen J Demarest
Journal:  J Biol Chem       Date:  2010-12-01       Impact factor: 5.157

Review 2.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

3.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 4.  Bispecific antibodies for viral immunotherapy.

Authors:  Elisabeth K Nyakatura; Alexandra Y Soare; Jonathan R Lai
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

Review 5.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

6.  Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Authors:  Birgit Dreier; Galina Mikheeva; Natalya Belousova; Petra Parizek; Edgar Boczek; Ilian Jelesarov; Patrik Forrer; Andreas Plückthun; Victor Krasnykh
Journal:  J Mol Biol       Date:  2010-11-05       Impact factor: 5.469

7.  Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium.

Authors:  C William Gundlach; Amy Caivano; Maria da Graca Cabreira-Hansen; Amir Gahremanpour; Wells S Brown; Yi Zheng; Bradley W McIntyre; James T Willerson; Richard A F Dixon; Emerson C Perin; Darren G Woodside
Journal:  Bioconjug Chem       Date:  2011-08-02       Impact factor: 4.774

8.  Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry.

Authors:  Séverine Fagète; François Rousseau; Giovanni Magistrelli; Franck Gueneau; Ulla Ravn; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  J Biol Chem       Date:  2011-10-31       Impact factor: 5.157

9.  Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

Authors:  Jennifer S Michaelson; Stephen J Demarest; Brian Miller; Aldo Amatucci; William B Snyder; Xiufeng Wu; Flora Huang; Samantha Phan; Sharon Gao; Adam Doern; Graham K Farrington; Alexey Lugovskoy; Ingrid Joseph; Veronique Bailly; Xin Wang; Ellen Garber; Jeff Browning; Scott M Glaser
Journal:  MAbs       Date:  2009-03-11       Impact factor: 5.857

10.  Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent.

Authors:  Séverine Fagète; Ulla Ravn; Franck Gueneau; Giovanni Magistrelli; Marie H Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2009 May-Jun       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.